All Videos

An expert discusses a 32-year-old woman with alopecia areata affecting eyebrows/eyelashes. Treatment options include topical/intralesional steroids, minoxidil, prostaglandin analogues, JAK inhibitors, and cosmetic approaches.

Tomassian noted unrealistic beauty standards fueled by social media filters and edited images have led to distorted expectations.

Christopher B. Zachary, MBBS, MRCP, FRCP, shares insights in apoptosis-based skin care treatment.

Panelists discuss how JAK inhibitors demonstrate significant efficacy in treating atopic dermatitis while examining their safety profiles and optimal positioning within the therapeutic landscape.

Panelists discuss how varying degrees of JAK selectivity in targeted therapies affect treatment outcomes, safety profiles, and therapeutic decision-making in atopic dermatitis management.

Elizabeth Berry, MD, FAAD, reviewed dysplastic nevi as risk markers and highlighted the need for more data on severe cases at AAD 2025.

Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C discuss the NEA's expanded eczema visual guide and upcoming Chicago event to support diverse patient communities.

By leveraging the innovative biomarker panels, clinicians can now offer more personalized and effective treatment options for psoriasis and AD.

The panelist discusses how the therapeutic options for atopic dermatitis have expanded significantly with the emergence of targeted biologics, oral agents, and refined topical treatments, transforming the management approach for patients across the disease spectrum.

Christopher Bunick, MD, PhD, reviewed the evolving role of antibiotics, emphasizing antibiotic stewardship, the gut-skin connection, and the importance of narrow-spectrum antibiotics at AAD 2025.

An expert discusses how UV radiation causes DNA damage, accelerating skin aging and cancer risk. Visible light and infrared radiation induce oxidative stress and hyperpigmentation, especially in darker skin tones. Conventional sunscreens shield against UV radiation but offer limited visible light and infrared protection. Mineral filters (zinc oxide, titanium dioxide) provide broad coverage, while chemical filters (oxybenzone, avobenzone) absorb UV radiation but lack efficacy against visible and infrared radiation.

An expert discusses how UV radiation makes up about 7% of the sun’s energy and penetrates the skin, causing aging, hyperpigmentation, and inflammation. Visible light and infrared radiation contribute to skin damage, with blue light being more harmful than red light due to its deeper penetration.

Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C, discuss redefining eczema flares to align clinical and patient perspectives.

Renata Block, MMS, PA-C, speaks with Wendy Smith Begolka, MBS, of the National Eczema Association about NEA’s strategic efforts in community outreach, health care provider engagement, and patient education.

Christopher Bunick, MD, PhD, discussed how to interpret recent benzene research as clinicians await regulatory guidance for benzoyl peroxide.

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

An expert discusses how alopecia areata significantly affects adolescent mental health. Treatment with ritlecitinib requires proper severity assessment via Severity of Alopecia Tool (SALT) score, clear communication of realistic timelines and goals, careful monitoring, and discussion of potential adverse effects. Long-term adherence is crucial for maintaining results.

An expert discusses how treatment for this adolescent boy with severe alopecia areata must balance efficacy with age-appropriate safety, considering psychological impact, growth/development factors, and family preferences while selecting among topical, intralesional, systemic, or emerging biologic options.

Lisa M. Arkin, MD, shared how early laser treatment and multidisciplinary approaches improves outcomes for vascular anomalies.

At AAD 2025, Karan Lal, DO, MS, FAAD, presented clinical insights on insulated microneedling tips, grounding pad issues in monopolar radiofrequency, and more.

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

Panelists discuss the areas of research that need more attention in pediatric atopic dermatitis (AD) management, highlighting gaps in understanding the long-term effects of treatments, the genetic underpinnings of the disease, and strategies for improving early diagnosis and personalized care.

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

Adamson dives deep into artificial intelligence, molecular testing, and melanoma overdiagnosis.

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.

April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.